Tumor microenvironmental modification by the current target therapy for head and neck squamous cell carcinoma

Current clinical and observational evidence supports the EXTREME regimen as one of the standards of care for patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) followed by the administration of immune checkpoint inhibitors (ICIs). In addition to the inhibition of the...

Descripción completa

Detalles Bibliográficos
Autores principales: Okuyama, Kohei, Naruse, Tomofumi, Yanamoto, Souichi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10161653/
https://www.ncbi.nlm.nih.gov/pubmed/37143088
http://dx.doi.org/10.1186/s13046-023-02691-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10161653/
https://www.ncbi.nlm.nih.gov/pubmed/37143088
http://dx.doi.org/10.1186/s13046-023-02691-4

Ejemplares similares